Avidity Biosciences
10578 Science Center Drive
Suite 125
San Diego
California
92121
United States
Tel: 858-401-7900
Website: http://www.aviditybiosciences.com/
Email: info@aviditybio.com
About Avidity Biosciences
Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people.
Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.
We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.
BeAVID
131 articles about Avidity Biosciences
-
Avidity Biosciences to Participate in Upcoming April 2024 Investor Conferences
3/27/2024
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating in the following upcoming conferences.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2024
3/21/2024
Avidity Biosciences, Inc. announced that on March 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,800 shares of its common stock and 15,400 restricted stock units to three new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
3/4/2024
Avidity Biosciences, Inc. announced new positive long-term AOC 1001 data from the MARINA open-label extension trial showing reversal of disease progression in people living with myotonic dystrophy type 1 across multiple endpoints including vHOT, muscle strength and activities of daily living when compared to END-DM1 natural history data.
-
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
2/29/2024
Avidity Biosciences, Inc. announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.
-
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
2/28/2024
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2023, and highlighted recent corporate progress.
-
Avidity Biosciences to Participate in Upcoming March 2024 Investor Conferences
2/27/2024
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following upcoming conferences.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 21, 2024
2/21/2024
Avidity Biosciences, Inc. announced that on February 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,500 shares of its common stock and 37,750 restricted stock units to five new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
2/20/2024
Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to AOC 1044.
-
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
2/15/2024
Avidity Biosciences, Inc. announced that the company will be presenting multiple posters from all three clinical development programs in rare muscle diseases, including new AOC 1001 long-term efficacy and safety data from the MARINA open-label extension trial in people living with myotonic dystrophy type 1 at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 22, 2024
1/22/2024
Avidity Biosciences, Inc. announced that on January 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,650 shares of its common stock and 18,825 restricted stock units to four new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
1/5/2024
Avidity Biosciences, Inc. today announced its 2024 corporate priorities and catalysts for the next stage of growth. In mid-2024, Avidity plans to initiate the global Phase 3 HARBOR™ trial of AOC 1001 for adults living with myotonic dystrophy type 1 (DM1).
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 21, 2023
12/21/2023
Avidity Biosciences, Inc. announced that on December 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,100 shares of its common stock and 3,550 restricted stock units to two new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers
12/13/2023
Avidity Biosciences today announced positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44™ clinical trial for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44).
-
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
11/28/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced a global licensing and research collaboration with Bristol Myers Squibb (NYSE: BMY) focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.
-
Building on a previous 2021 collaboration, Bristol Myers Squibb is paying $100 million upfront for the development of five cardiovascular targets utilizing Avidity Biosciences’ antibody oligonucleotide conjugates.
-
Avidity Biosciences to Participate in Upcoming Investor Conference - November 21, 2023
11/21/2023
Avidity Biosciences, Inc. today announced that Avidity management will be participating at the following upcoming conference.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 21, 2023
11/21/2023
Avidity Biosciences, Inc. announced that on November 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 27,000 shares of its common stock and 13,500 restricted stock units to eight new non-executive employees under the Avidity Biosciences, Inc.
-
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
11/8/2023
Avidity Biosciences, Inc. reported financial results and recent highlights for the third quarter ended September 30, 2023.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 23, 2023
10/23/2023
Avidity Biosciences, Inc. announced that on October 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,200 shares of its common stock and 48,100 restricted stock units to twelve new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
10/7/2023
Avidity Biosciences, Inc. announced new positive AOC 1001 data demonstrating improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1.